Investigator

Léticia Montes Stark

Universidade Federal Do Tringulo Mineiro

LMSLéticia Montes St…
Papers(1)
Pathways of IFN-alpha…
Collaborators(6)
Márcia Antoniazi Mich…Nelson Ranieri TironeCarolina Guissoni Cam…Eddie Fernando Candid…Jéssica Ferreira Viei…Kézia Jesus Aguiar Fe…
Institutions(1)
Universidade Federal …

Papers

Pathways of IFN-alpha Activation in Patients with Cervical Intraepithelial Neoplasia (CIN)

Abstract Objective The aim of the present study was to compare the local and systemic expression of the factors linked to the interferon alpha (IFN-α) activation pathway in different degrees of cervical intraepithelial neoplasia (CIN) and cervical cancer. Methods A total of 128 patients with CIN I, CIN II, CIN III and cervical cancer was evaluated. The real-time polymerase chain reaction (RT-PCR) technique was used to evaluate the gene expression of IFNR1, IFNR2, IFN-α, oligoadenylate synthase (2'5′OAS), cytokine signal suppressor 1 (SOCS) 1, SOCS3, signal transducer and transcription activator 1 (STAT1), and IRF9 from 128 biopsies. A total of 46 out of 128 samples were evaluated by flow cytometry for IFNAR1, IFNAR2, STAT1, IRF7 and IFN-α in peripheral blood cells. Results Patients with CIN II and III (63 samples) had a low local expression of IFNR1, but not IFNR2. Patients with some degree of injury showed high expression of SOCS1 and SOCS3. Systemically, patients with CIN II and III (20 samples) had a significant increase in IFNR1, IFNR2, STAT1, IRF7, and IFN-α in helper, cytotoxic T lymphocytes, and in monocytes. Conclusion Patients with high-grade lesions have increased systemic expression of IFN-α and its activation pathways in helper and cytotoxic T lymphocytes, as well as in monocytes due to an exacerbation of the immune response in these patients. This phenomenon is not accompanied by resolution of the lesion due to a defect in the IFN-α activation pathway that revealed by low local IFNAR1 expression and high local expression of SOCS1 and SOCS3.

3Works
1Papers
6Collaborators

Education

2018

Pós-doutorado

Universidade Federal do Triângulo Mineiro · Instituto de Pesquisa em Oncologia

2017

Doutora em Ciências da Saúde

Universidade Federal do Triângulo Mineiro · Instituto de Pesquisa em Oncologia

2012

Mestre em Patologia

Universidade Federal do Triângulo Mineiro · Instituto de Pesquisa em Oncologia

2009

Biomedicina

Universidade de Uberaba